Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label study

医学 内科学 胃肠病学 边缘区B细胞淋巴瘤 临床终点 淋巴瘤 粘膜相关淋巴组织 临床研究阶段 不利影响 无进展生存期 B症状 进行性疾病 边缘地带 马尔特淋巴瘤 肿瘤科 临床试验 化疗 B细胞 免疫学 抗体
作者
Lijuan Deng,Zhiming Li,Huilai Zhang,Haiwen Huang,Jianda Hu,Lihong Liu,Ting Liu,Jie Jin,Zunmin Zhu,Wenyu Li,Zhenqian Huang,Wenrong Huang,Keshu Zhou,Haiyan Yang,Mingzhi Zhang,Kaiyang Ding,Hui Zhou,Yu Hu,Yue-Rong Shuang,Junning Cao
出处
期刊:American Journal of Hematology [Wiley]
卷期号:98 (11): 1742-1750 被引量:12
标识
DOI:10.1002/ajh.27064
摘要

Marginal zone lymphoma (MZL) is an indolent type of non-Hodgkin lymphoma that develops through pathological B cell receptor signaling. Orelabrutinib, a new-generation oral small molecule Bruton's tyrosine kinase inhibitor, was evaluated in relapsed/refractory (r/r) MZL patients. Previously treated r/r MZL patients received orelabrutinib 150 mg once daily in a phase 2, multicenter, single-arm study conducted in China. The primary endpoint was overall response rate (ORR) assessed by an Independent Review Committee (IRC) based on the Lugano 2014 classification. Other efficacy, safety, and pharmacokinetic profiles were evaluated as secondary outcome measures. A total of 111 patients were enrolled, of which 90 patients had MZL confirmed by central pathology review, who were mainly with extra-nodal MZL of mucosa-associated lymphoid tissue (MALT, 46.7%) and nodal MZL (35.6%). The majority had late-stage disease, with stage IV accounting for 75.6%. After a median follow-up duration of 24.3 months, the IRC-assessed ORR was 58.9% (95% confidence interval [CI], 48.0-69.2), with rates of complete response and partial response being 11.1% and 47.8%, respectively. The IRC-assessed median duration of response was 34.3 months, and the IRC-assessed median progression-free survival (PFS) was not reached with a 12-month PFS rate of 82.8% (95% CI, 72.6-89.5). The rate of overall survival at 12 months was 91.0% (95% CI, 82.8-95.4). Common all-grade treatment-related adverse events (TRAEs) included anemia (27.9%), neutrophil count decrease (23.4%), white blood cell count decrease (18.0%), platelet count decrease (17.1%), blood present in urine (16.2%), rash (14.4%), and upper respiratory tract infection (10.8%). Thirty-four patients (30.6%) experienced grade 3 or higher TRAEs. Serious TRAEs occurred in 18 patients (16.2%), of which pneumonia (5.4%) was the most common. Seven patients (6.3%) discontinued orelabrutinib due to TRAEs. Orelabrutinib demonstrated high response rates with durable disease remission and was well tolerated in Chinese patients with r/r MZL.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
邓先桂完成签到,获得积分10
1秒前
charry发布了新的文献求助10
1秒前
1秒前
1秒前
万能图书馆的应助被米娅采纳,获得10
2秒前
初景的应助被niko采纳,获得20
2秒前
wisper完成签到,获得积分10
2秒前
南风喜欢发布了新的文献求助10
3秒前
4秒前
科研通AI6.4的应助被DW采纳,获得10
4秒前
archer完成签到,获得积分10
5秒前
智智完成签到 ,获得积分10
5秒前
lovt123完成签到,获得积分10
5秒前
6秒前
四喜丸子完成签到,获得积分10
6秒前
风朝东发布了新的文献求助10
7秒前
冷落清秋完成签到 ,获得积分10
8秒前
muderder发布了新的文献求助10
9秒前
9秒前
lxy发布了新的文献求助10
9秒前
希望天下0贩的0的应助被archer采纳,获得10
9秒前
科研通AI6.3的应助被wang采纳,获得10
10秒前
酷波er的应助被SKHC采纳,获得10
10秒前
东方自远完成签到,获得积分10
10秒前
cyy关注了科研通微信公众号
10秒前
12秒前
华夫饼发布了新的文献求助10
12秒前
星星发布了新的文献求助10
12秒前
13秒前
这题不讲发布了新的文献求助10
14秒前
五号发布了新的文献求助10
14秒前
15秒前
大模型的应助被刘辞忧采纳,获得10
15秒前
Maestro_S的应助被DW采纳,获得50
16秒前
米娅发布了新的文献求助10
17秒前
稻草熊完成签到,获得积分10
17秒前
Jasper的应助被风朝东采纳,获得10
19秒前
19秒前
clp必发sci完成签到 ,获得积分10
20秒前
cdercder的应助被jay采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188249
求助须知:如何正确求助?哪些是违规求助? 9576071
关于积分的说明 21845183
捐赠科研通 7786256
什么是DOI,文献DOI怎么找? 3435261
关于科研通互助平台的介绍 2559559
邀请新用户注册赠送积分活动 2482169